Should I buy or sell Relay Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RLAY shares. View RLAY analyst ratings or view top-rated stocks .

What is Relay Therapeutics' stock price target for 2024?

10 brokers have issued 12 month price targets for Relay Therapeutics' stock. Their RLAY share price targets range from $12.50 to $33.00. On average, they expect the company's stock price to reach $23.69 in the next year. This suggests a possible upside of 279.6% from the stock's current price. View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts .

How have RLAY shares performed in 2024?

Relay Therapeutics' stock was trading at $11.01 at the beginning of 2024. Since then, RLAY stock has decreased by 43.3% and is now trading at $6.24. View the best growth stocks for 2024 here .

When is Relay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RLAY earnings forecast .

How were Relay Therapeutics' earnings last quarter?

Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its earnings results on Thursday, February, 22nd. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative trailing twelve-month return on equity of 42.43%. During the same quarter in the prior year, the business posted ($0.56) EPS.

What ETFs hold Relay Therapeutics' stock?

ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . TrueShares Technology, AI & Deep Learning ETF (LRNZ) .

What other stocks do shareholders of Relay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND) , CureVac (CVAC) , QuidelOrtho (QDEL) , Teladoc Health (TDOC) , Tesla (TSLA) , Datadog (DDOG) , DraftKings (DKNG) , eHealth (EHTH) , GoHealth (GOCO) and Intel (INTC) .

When did Relay Therapeutics IPO?

Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.

Who are Relay Therapeutics' major shareholders?

Relay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.11%), TrueMark Investments LLC (0.04%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andy Porter , Brian Adams , Donald A Bergstrom , Mark Murcko, Peter Rahmer, Sanjiv Patel and Thomas Catinazzo . View institutional ownership trends .

How do I buy shares of Relay Therapeutics?

Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:RLAY

Relay Therapeutics (RLAY) Stock Price, News & Analysis

→ Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad)

Free RLAY Stock Alerts

$6.24

+0.03 (+0.48%)

(As of 01:58 PM ET)

Compare

Today's Range: $5.95
▼
$6.40
50-Day Range: $6.21
▼
$10.84
52-Week Range: $5.95
▼
$13.32

Volume: 967,354 shs
Average Volume: 1.11 million shs
Market Capitalization: $818.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.69

Get Relay Therapeutics alerts:

Relay Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 279.6% Upside
$23.69 Price Target
Short Interest: Bearish
8.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 3 Articles This Week
Insider Trading: Selling Shares
$43,814 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.84) to ($2.69) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Medical Sector

475th out of 914 stocks

Biological Products, Except Diagnostic Industry

79th out of 152 stocks

3.5

Analyst's Opinion

Consensus Rating
Relay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Relay Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.52% of the outstanding shares of Relay Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Relay Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
Change versus previous month
Short interest in Relay Therapeutics has recently decreased by 5.42%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Relay Therapeutics does not currently pay a dividend.
Dividend Growth
Relay Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RLAY.

2.6

News and Social Media Coverage

News Sentiment
Relay Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Relay Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
11 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,814.00 in company stock.
Percentage Held by Insiders
Only 3.54% of the stock of Relay Therapeutics is held by insiders.
Percentage Held by Institutions
96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Relay Therapeutics are expected to grow in the coming year, from ($2.84) to ($2.69) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Relay Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Relay Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Relay Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad GoldenCrest Metals

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

Learn More Now

About Relay Therapeutics Stock (NASDAQ:RLAY)

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

RLAY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RLAY Stock News Headlines

April 11, 2024 | globenewswire.com

Relay Therapeutics to Participate in Upcoming Investor Conferences

April 11, 2024 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of "Moderate Buy" from Analysts

April 18, 2024 | GoldenCrest Metals (Ad)

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

March 19, 2024 | markets.businessinsider.com

Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction

March 16, 2024 | finance.yahoo.com

RLAY Apr 2024 7.500 call

March 16, 2024 | finance.yahoo.com

RLAY Apr 2024 7.500 put

March 15, 2024 | investorplace.com

3 Precision Medicine Stocks That Could Benefit From the Industry's Rise

March 13, 2024 | seekingalpha.com

Relay Therapeutics: Platform More Important Than Programs

April 18, 2024 | GoldenCrest Metals (Ad)

Emergency: Biden's $20 Trillion Mistake Could Cost YOU!

The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.

February 26, 2024 | globenewswire.com

Relay Therapeutics to Participate in Three Upcoming Investor Conferences

February 26, 2024 | markets.businessinsider.com

Relay Therapeutics: Strong Buy on Improved Financials and Promising Future Milestones

February 25, 2024 | fool.com

Relay Therapeutics (NASDAQ: RLAY)

February 24, 2024 | finance.yahoo.com

Relay Therapeutics Full Year 2023 Earnings: Beats Expectations

February 23, 2024 | finanznachrichten.de

Relay Therapeutics, Inc.: Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

February 22, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Relay Therapeutics: Strong Financial Standing and Strategic Pipeline Focus

February 22, 2024 | finance.yahoo.com

Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights

February 22, 2024 | globenewswire.com

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

February 21, 2024 | benzinga.com

Relay Therapeutics's Earnings: A Preview

February 21, 2024 | investing.com

Relay Therapeutics Inc (RLAY)

February 17, 2024 | finance.yahoo.com

RLAY Mar 2024 7.500 put

February 16, 2024 | finance.yahoo.com

VERV Mar 2024 12.500 call

February 15, 2024 | finance.yahoo.com

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

February 15, 2024 | globenewswire.com

Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024

February 15, 2024 | markets.businessinsider.com

Relay Therapeutics Poised for Growth with Promising RLY-2608, Analyst Maintains Buy Rating

February 15, 2024 | finance.yahoo.com

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

February 12, 2024 | seekingalpha.com

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

February 1, 2024 | finance.yahoo.com

Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

See More Headlines

Receive RLAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:RLAY
CUSIP: N/A
CIK: 1812364
Web: www.relaytx.com
Phone: 617-370-8837
Fax: N/A
Employees: 323
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.69
High Stock Price Target: $33.00
Low Stock Price Target: $12.50
Potential Upside/Downside: +279.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-341,970,000.00
Net Margins: -1,263.49%
Pretax Margin: -1,338.66%
Return on Equity: -42.43%
Return on Assets: -36.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 25.44
Quick Ratio: 25.44

Sales & Book Value

Annual Sales: $25.55 million
Price / Sales: 32.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.90 per share
Price / Book: 1.06

Miscellaneous

Outstanding Shares: 131,180,000
Free Float: 126,535,000
Market Cap: $818.56 million
Optionable: Optionable
Beta: 1.63

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Alexis A. Borisy A.M. (Age 52)
Co-Founder & Independent Chairman
Comp: $85k
Dr. Sanjiv K. Patel M.A. (Age 50)
M.B.A., M.D., MBBS, CEO, President & Director
Comp: $1.03M
Dr. Mark Murcko Ph.D. (Age 64)
Co-Founder & Director
Comp: $50k
Mr. Thomas Catinazzo (Age 47)
Chief Financial Officer
Comp: $599.83k
Mr. Brian R. Adams J.D. (Age 50)
Chief Legal Officer & Secretary
Comp: $598.53k
Dr. Donald A. Bergstrom M.D. (Age 52)
Ph.D., President of Research & Development
Comp: $711.25k
Mr. Peter Rahmer
Chief Corporate Development Officer
Dr. Deborah Palestrant M.B.A.
Ph.D., Vice President of Corporate Development & Strategy
Mr. Jim Watters Ph.D.
Chief Scientific Officer of Late Research
Dr. Beni B. Wolf M.D.
Ph.D., Chief Medical Officer & Head of Precision Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RLAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Relay Therapeutics stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relay Therapeutics in the last year. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RLAY shares.
View RLAY analyst ratings or view top-rated stocks.
What is Relay Therapeutics' stock price target for 2024?: 10 brokers have issued 12 month price targets for Relay Therapeutics' stock. Their RLAY share price targets range from $12.50 to $33.00. On average, they expect the company's stock price to reach $23.69 in the next year. This suggests a possible upside of 279.6% from the stock's current price.
View analysts price targets for RLAY or view top-rated stocks among Wall Street analysts.
How have RLAY shares performed in 2024?: Relay Therapeutics' stock was trading at $11.01 at the beginning of 2024. Since then, RLAY stock has decreased by 43.3% and is now trading at $6.24.
View the best growth stocks for 2024 here.
When is Relay Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RLAY earnings forecast.
How were Relay Therapeutics' earnings last quarter?: Relay Therapeutics, Inc. (NASDAQ:RLAY) posted its earnings results on Thursday, February, 22nd. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.09. Relay Therapeutics had a negative net margin of 1,263.49% and a negative trailing twelve-month return on equity of 42.43%. During the same quarter in the prior year, the business posted ($0.56) EPS.
What ETFs hold Relay Therapeutics' stock?: ETFs with the largest weight of Relay Therapeutics (NASDAQ:RLAY) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

What other stocks do shareholders of Relay Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Relay Therapeutics investors own include Beyond Meat (BYND), CureVac (CVAC), QuidelOrtho (QDEL), Teladoc Health (TDOC), Tesla (TSLA), Datadog (DDOG), DraftKings (DKNG), eHealth (EHTH), GoHealth (GOCO) and Intel (INTC).
When did Relay Therapeutics IPO?: Relay Therapeutics (RLAY) raised $250 million in an initial public offering (IPO) on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO.
Who are Relay Therapeutics' major shareholders?: Relay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Congress Asset Management Co. MA (0.11%), TrueMark Investments LLC (0.04%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andy Porter, Brian Adams, Donald A Bergstrom, Mark Murcko, Peter Rahmer, Sanjiv Patel and Thomas Catinazzo.
View institutional ownership trends.
How do I buy shares of Relay Therapeutics?: Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLAY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial